Cardiac and pulmonary late effects do not negatively influence performance status and non‐relapse mortality of children surviving five yr after autologous hematopoietic cell transplantation: Report from the EBMT Paediatric Diseases and Late Effects Working Parties

Abstract:  The current prospective study dealt with clinical outcome associated with pulmonary and cardiac late effects of AuHCT in children with malignancies. We prospectively evaluated 58 children, utilizing pulmonary function tests and cardiac shortening fraction, performed in pre‐AuHCT phase and then annually. The overall five‐yr survival was 68%. The five‐yr cumulative incidence of lung and cardiac function impairment in survivors was 21% in both cases. None of the patients presented with restrictive or obstructive pulmonary pathology at the last follow‐up and performance status for all survivors, ranged from 90% to 100%. The cumulative incidence of non‐relapse mortality was 12.6% (range 6.3–25.3%), whereas relapse mortality was 19.7% (range 11.6–33.5). In conclusion, our study shows no significant deterioration in post‐AuHCT pulmonary and cardiac function and in particular, no negative impact of lung and heart late effects on performance status and non‐relapse mortality.

[1]  C. Ronckers,et al.  Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. , 2007, Blood.

[2]  F. Tana,et al.  Impact of cumulative anthracycline dose, preparative regimen and chronic graft-versus-host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: a prospective evaluation on behalf of the EBMT Pediatric Diseases and Late Effects Workin , 2007, Bone Marrow Transplantation.

[3]  J. Wingard,et al.  Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Mar , 2006, Bone Marrow Transplantation.

[4]  J. Steinberger,et al.  Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. , 2005, Blood.

[5]  B. Storer,et al.  Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K. Ness,et al.  Performance limitations and participation restrictions among childhood cancer survivors treated with hematopoietic stem cell transplantation: the bone marrow transplant survivor study. , 2005, Archives of pediatrics & adolescent medicine.

[7]  A. Nademanee,et al.  Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. , 2005, Blood.

[8]  L. Rybicki,et al.  Clinical outcomes of patients with impaired left ventricular ejection fraction undergoing autologous bone marrow transplantation: can we safely transplant patients with impaired ejection fraction? , 2004, Bone Marrow Transplantation.

[9]  S. Heckbert,et al.  Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation. , 2003, American journal of respiratory and critical care medicine.

[10]  A. Cnaan,et al.  Longitudinal evaluation of cardiopulmonary performance during exercise after bone marrow transplantation in children. , 2000, The Journal of pediatrics.

[11]  B. Suys,et al.  Dobutamine Stress Echocardiography in the Evaluation of Late Anthracycline Cardiotoxicity in Childhood Cancer Survivors , 1996, Pediatric Research.

[12]  M. Galli,et al.  Cardiac and respiratory function after bone marrow transplantation in children with leukaemia. , 1995, Bone marrow transplantation.

[13]  H. Deeg,et al.  Abnormalities of pulmonary function tests after marrow transplantation predict nonrelapse mortality. , 1995, American journal of respiratory and critical care medicine.

[14]  J. Hankinson,et al.  Acceptability and reproducibility criteria of the American Thoracic Society as observed in a sample of the general population. , 1991, The American review of respiratory disease.

[15]  J. Stockman Performance Limitations and Participation Restrictions Among Childhood Cancer Survivors Treated With Hematopoietic Stem Cell Transplantation: The Bone Marrow Transplant Survivor Study , 2007 .

[16]  Standardization of spirometry--1987 update. Official statement of American Thoracic Society. , 1987, Respiratory care.